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Abstract 
 
Cardiac K+ channels are cardiomyocyte membrane proteins that regulate K+ ion flow across the cell 
membrane on the electrochemical gradient, and determine the resting membrane potential and the 
cardiac action potential morphology and duration. Several K+ channels have been well studied in the 
human heart. They include the transient outward K+ current Ito1, the ultra-rapidly delayed rectifier 
current IKur, the rapidly and slowly delayed rectifier currents IKr and IKs, the inward rectifier K+ current 
IK1, and ligand-gated K+ channels, including ATP-sensitive K+ current (IKATP) and 
acetylcholine-activated current (IKACh). Regional differences of K+ channel expression contribute to the 
variable morphologies and durations of cardiac action potentials from sinus node and atrial to 
ventricular myocytes, and different ventricular layers from endocardium and midmyocardium to 
epicardium. They also show different responses to endogenous regulators and/or pharmacological 
agents. K+ channels are well-known targets for developing novel antiarrhythmic drugs that can 
effectively prevent/inhibit cardiac arrhythmias. Especially atrial specific K+ channel currents (IKur and 
IKACh) are the targets for developing atrial-selective anti-atrial fibrillation drugs, which has been greatly 
progressed in recent years. This chapter concentrates on recent advances in intracellular signaling 
regulation and pharmacology of cardiac K+ channels under physiological and pathophysiological 
conditions.   
 
 
 
Abbreviations: AF, atrial fibrillation; IKur, ultra-rapidly delayed rectifier K+ current; Ito1, transient 
outward K+ current; IKACh, acetylcholine-activated K+ current; IKATP, ATP-sensitive K+ current; IKr, 
rapidly delayed rectifier K+ current; IKs, slowly delayed rectifier K+ current; hERG, human 
ether-à-go-go–related gene; Kir, inward rectifier K+ channels; SUR, sulfonylurea receptor; K2p, two 
pore K+ channels;  ECG, electrocardiogram; EADs, early afterdepolarizations; TdPs, Torsade de Pointes; 
APD, action potential duration; 4-AP, 4-aminopyrodine; ERP, effective refractory period; LQTs, long 
QT syndrome; SQTs, short QT syndrome; PKA, protein kinase A; PLC, phospholipase C; PKC, protein 
kinase C; PTK, protein tyrosine kinase; CaMKII, Ca2+/calmodulin-dependent protein kinase II; PIP2, 
phosphatidylinositol 4,5-bisphosphate; EGFR, epidermal growth factor receptor; sarcKATP, 
sarcolemmal ATP-sensitive K+ channels; mitoKATP, mitochondrial ATP-sensitive K+ channels ; TMD, 
Transmembrane domains 
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1.  Introduction 
Cardiac K+ channels play a pivotal role in maintaining normal cardiac electrical activity. They regulate the 
resting membrane potential and excitability, participate in the repolarization and determine the shape and 
duration of cardiac action potential. Malfunction of K+ channels, due to either congenital encoded gene 
mutations or drug blockade, alters not only the cardiomyocyte excitability, but also the electrical balance of 
depolarization and repolarization and thus causes a long QT interval or short QT interval of the 
electrocardiogram and underlies different types of cardiac arrhythmias (Kannankeril and Roden, 2007; 
Zareba and Cygankiewicz, 2008). Therefore, cardiac K+ channels are important targets of antiarrhythmic 
drugs. 
 It is well recognized that the shape and duration of cardiac action potential are determined by a balance 
(i.e. sequential activation and inactivation) of inward currents and outward currents (Nerbonne and Kass, 
2005). Figure 1 schematically illustrates the time course of different current contribution to the action 
potentials of human atrial and ventricular myocytes. The inward currents include voltage-gated Na+ current 
(INa) responsible for the phase 0 depolarization and L-type Ca2+ current (ICa.L) responsible for maintaining 
plateau (phase 2) of the action potential. The inward component of electrogenic Na+-Ca2+ exchanger may 
also contribute to the phase 2 of the action potential.    
 The outward currents are mainly carried by different K+ channels in human cardiac myocytes. They 
contribute to repolarization of different phases of the action potential. These K+ currents include the inward 
rectified K+ current IK1, the transient outward K+ current Ito1, the ultra-rapidly delayed rectifier K+ current IKur, 
rapidly and slowly delayed rectifier K+ currents (IKr and IKs), acetylcholine-regulated K+ current (IKACh), and 
ATP-sensitive K+ current (IK.ATP).   
2.  K+ channel classification. 
I.  Diversity of K+ channels 
K+ channels are the most widely distributed type of ion channels composed of α-subunits and β-subunits 
(Snyders, 1999).  The α-subunits of K+ channels are characterized by 1) an ion conducting pore through 
which K+ ions pass through the plasma membrane; 2) a K+ selectivity filter in the P loop from each subunit 
which have their electro-negative carbonyl oxygen atoms aligned towards the centre of the filter pore and 
form an anti-prism similar to a water solvating shell around each K+ binding site;  and 3) a gating machinery 
that controls the switch between open and close states in response to either changes in membrane potential or 
a ligand  (Snyders, 1999). The cytoplasmic N- and C-termini of α-subunits are also important functional 
domains. The pore-forming subunits homogenously form functional channels (MacKinnon, 1995).  K+ 
channels have a tetrameric structure in which four identical α-subunits associate to form a fourfold 
symmetric complex arranged around a central ion conducting pore (MacKinnon, 1995). Alternatively four 
related but not identical α-subunits may associate to form heterotetrameric complexes.   
 The classification of K+ channels is based upon the primary amino acid sequence of the pore-containing 
α-subunits. Three groups (Fig. 2) with six, two, or four putative transmembrane segments are recognized, 
including 1) voltage-gated K+ (Kv) channels containing six transmembrane regions (S1-S6) with a single 
pore loop formed by the S5 and S6 segments and S5-S6 linker. The S4 segment is rich in positively charged 
residues and serves as the voltage sensor (e.g.  Ito1, IKur, IKr, and IKs); 2) inward rectifier K+ (Kir) channels 
containing two transmembrane domains (M1-M2) with intracellular N- and C-termini, and a single pore loop 
formed by the M1 and M2 domains (e.g. IK1, IKACh, and IKATP); and 3) two-pore K+ (KP2) channels containing 
four transmembrane domains (M1-M4), intracellular N- and C-terminus, and two pore regions related to 
background or leak channels (e.g. TWIK, TASK, TREK and THIK) (Gurney and Manoury, 2009; Snyders, 
1999).  
II.  β-Subunits of K+ channels 
Most K+ channels heterogeneously assemble with the auxiliary β-subunits in native cells (Fig. 2). The 
β-subunits are either cytoplasmic proteins (e.g. Kvβ1-4, KChIP) or transmembrane proteins, such as minK 
and minK-related proteins (MiRPs) encoded by KCNE gene family, and large ATP binding cassette (ABC) 
transport-related proteins, such as the sulfonylurea receptors (SUR) for the inward rectifiers Kir6.1–6.2 
(Snyders, 1999; Stephan et al., 2006). Most β-subunits assemble with α-subunits and act as a molecular 
chaperone of the α-subunits in regulating the channel gating kinetics, pharmacology, folding/coassembly, 
trafficking or cell surface expression (Bett and Rasmusson, 2008; Martens et al., 1999; Xu et al., 2009). Both 
α-subunits and β-subunits are pharmacological targets. Cardiac K+ channels are also regulated by numerous 
endogenous molecules and signals. The complex interaction between α-subunits, β-subunits and endogenous 
modulators represents diversity of native cardiac potassium currents (Snyders, 1999). 
3. Cardiac voltage-gated K+ (Kv) channels 
I. The transient outward K+ current Ito1
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The transient outward current Ito, is composed of two components, i.e. 4-aminopyridine (4-AP) sensitive 
transient outward K+ current (Ito1) and Ca2+-activated transient outward Cl− current (Ito2) in some species (Li 
et al., 1995).  Ito2 is not present in human cardiac myocytes, and therefore is not discussed here. Ito1 is a 
voltage-gated and Ca2+-independent K+ current that is rapidly activated and inactivated in response to 
depolarization, and contributes to the early repolarization (phase 1) of the action potential in human cardiac 
myocytes (Fig. 1). Density of Ito1 is greater in atria than ventricles, and is 3-4 folds greater in ventricular 
midmyocardial (M) cells and/or subepicardial cells than in subendocardial cells (Li et al., 1995; Li et al., 
1998), therefore Ito1 contributes significantly to the phase 1 of the action potentials in these regional 
myocytes to maintain normal cardiac heterogeneous electrophysiology.  
A. Molecular identification of Ito1  
Kv4.3 (KCND3) is the dominant candidate coding for cardiac Ito1 in human hearts (Dixon et al., 1996).  
Kv4.3 channel mRNA and/or protein are significantly expressed in human atrium and ventricle (Gaborit et 
al., 2007; Kaab et al., 1998) and in canine hearts (Zicha et al., 2004), and display a gradient expression in 
human and canine ventricular wall from endocardium to epicardium (Zicha et al., 2004), comparable to the 
region-dependent Ito1 (Li et al., 1998; Liu et al., 1993; Nabauer et al., 1996). Kv4.3 assembles with 
cytoplasmic KChIPs to form Ito1 channels (Zicha et al., 2004). In addition, DPP6 (dipeptidyl 
aminopeptidase-like protein 6) is another putative subunit of cardiac Kv4.3 (Radicke et al., 2005). Moreover, 
the potential contribution of Kv1.4 channels to human ventricular Ito1 can not be excluded (Po et al., 1992; 
Snyders, 1999).     
The downregulation of cardiac Ito1 frequently occurs in failing hearts associated with a prolonged APD 
(Li et al., 2002; Li et al., 2004). The reduction of Ito1 likely contributes to the diminished phase 1 amplitude 
of action potential, and also partially to the prolonged APD and early afterdepolarizations (EADs) in failing 
hearts (Li et al., 2002; Li et al., 2004). In patient with chronic atrial fibrillation (AF) and canine with 
experimental AF, atrial Ito1 and/or Kv4.3 gene and/or protein are also downregulated (Brundel et al., 2001; 
Grammer et al., 2000; Yue et al., 1999).   
B. Signaling regulation of Ito1
The gating properties and kinetics of cardiac Ito1 are modulated by various endogenous molecules and signal 
pathways including serine/threonine and tyrosine phosphorylation. α-Adrenergic stimulation inhibits cardiac 
Ito1 in rabbit ventricular myocytes (Fedida et al., 1990) and in human cardiac myocytes and cloned hKv4.3 
current expressed in mammalian cells (Po et al., 2001), which may be mediated by  protein kinase C (PKC), 
since the PKC activator phorbol 12-myristate 13-acetate (PMA) exhibits a similar inhibition of rat cardiac 
Ito1 and Kv4.2/Kv4.3 currents (Nakamura et al., 1997). In addition, c-Src tyrosine kinase increases hKv4.3 
current by phosphorylating the channels through the associated macromolecular complex, which is mediated 
by the SH2 and SH3 domains of c-Src kinases (Gomes et al., 2008).  
Activation of Ca2+/calmodulin-dependent protein kinase II (CaMKII) slows the inactivation and 
accelerates the recovery from inactivation of Kv4.3 channels via directly phosphorylating S550 located in 
C-terminus (Sergeant et al., 2005). SAP97, one of the membrane-associated guanylate kinase proteins, 
participates in CaMKII dependent regulation of cardiac Kv4.3/Kv4.2 channels (El-Haou et al., 2009). Nitric 
oxide is a diffusible messenger that inhibits Kv4.3 channels and human Ito1 mediated by activating adenylate 
cyclase and the subsequent activation of PKA and the serine/threonine phosphatase 2A (Gomez et al., 2008). 
The increase of the bioavailability of atrial nitric oxide could partially restore the duration of the plateau 
phase of remodeled action potential by inhibiting I . to1 Angiotensin II regulates the membrane distribution 
and gating properties of Kv4.3 channels (Doronin et al., 2004).  
C.  Pharmacology of Ito1
4-AP is the first compound used by Kenyon and Gibbon to separate Ito1 from Ito2 (or ICa.Cl) in sheep Purkinje 
fibers (Kenyon and Gibbons, 1979). It is then widely employed as a pharmacological tool to separate Ito1 
from other currents (Li et al., 1995).  Ito1 is a major repolarization current in human atrium.  The blockade of 
Ito1 is supposed to prolong atrial APD and the refractory period and therefore exert anti-arrhythmic effect.  
Several antiarrhythmic drugs inhibit Ito1 in human atrial myocytes (see review by Tamargo et al., 2004). The 
class I anti-arrhythmic drug flecainide blocks inactivated Ito1 in a frequency-independent manner (Wang et 
al., 1995), and quinidine shows an open channel blocker of Ito1 in a frequency-dependent manner. 
Propafenone blocks human atrial Ito1 in a voltage- and use-independent fashion (Seki et al., 1999). 
Ambasilide inhibits Ito1 without affecting voltage-dependence of activation, inactivation, or recovery from 
inactivation, but accelerates the inactivation of Ito1, suggesting an open-channel block (Feng et al., 1997).  
In addition, Ca2+ channel antagonists (diltiazem and nifedipine) inhibit Ito1 in human atrial myocytes 
(Gao et al., 2005). Raloxifene, a selective estrogen receptor modulator, directly inhibits human atrial Ito1 (Liu 
et al., 2007). The antifungal antibiotic clotrimazole inhibits Ito1 by accelerating the inactivation and slowing 
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the recovery from inactivation of the channels (Tian et al., 2006). The antihistamine drug loratadine 
rate-dependently inhibits Ito1 at a therapeutic concentration (10 nM) (Crumb, 1999). The omega-3 (n-3) 
polyunsaturated fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) from fish oil 
inhibit human atrial Ito1 in a concentration-dependent manner (Li et al., 2009) (Table 1).   
II. The ultra-rapidly delayed rectifier K+ current IKur
IKur is a rapid activation and slow inactivation K+ current (Snyders et al., 1993; Wang et al., 1993). It is 
functionally present in the atria but not in the ventricles of human heart (Li et al., 1996). IKur is thought to be 
a promising molecular target for atrial arrhythmia (Ford and Milnes, 2008; Kozlowski et al., 2009; Tamargo 
et al., 2009). IKur is also observed in canine (Fedida et al., 2003; Yue et al., 1996), pig (Li et al., 2004) and rat 
(Boyle and Nerbonne, 1992) atrial myocytes. 
A.  Molecular identification of IKur
Kv1.5 (KCNA5) encodes the pore-forming subunit of human atrial IKur (Snyders, 1999; Fedida et al., 1993), 
which is supported by the evidence that Kv1.5 antisense oligodeoxynucleotides specifically inhibits IKur 
density in human atrial myocytes (Feng et al., 1997), and Kv1.5 gene is significantly expressed in human 
atrium (Gaborit et al., 2007). In canine atrium, IKur is initially found to be encoded by Kv3.1 (Yue et al., 
1996); however, a later study confirms that Kv1.5 does encode the IKur in canine atrial myocytes (Fedida et 
al., 2003). The finding of the later study makes it possible to use canine model in evaluating IKur/Kv1.5 
blockers for the treatment of AF (Li et al., 2008). In addition, Kv1.5 mRNA and protein, responsible for IKur, 
are present in mouse and rat hearts (Nerbonne, 2000).  Moreover, Kv1.5 transcripts are also detected in 
extracardiac tissues, e.g. pituitary gland, brain, pancreas, etc (Takimoto et al., 1993). 
Multiple members of a Kvβ1 subunit family for Kv1.5 have been cloned and multiple N-terminal splice 
isoforms were detected (Snyders, 1999). Kvβ1 encodes the ancillary subunit (Martens et al., 1999) of IKur 
channels. Co-expression of accessory Kvβ-subunits (Kvβ-1.2/1.3) increases the inactivation of Kv1.5 
channels and the sensitivity to channel phosphorylation by PKA and/or PKC (Kwak et al., 1999).  
In chronic AF, IKur density, Kv1.5 mRNA and protein (like other ion currents, including Ito1, ICa.L, and 
INa) are downregulated (Brundel et al., 2001; Grammer et al., 2000). Loss of function of mutant Kv1.5 
channels however may lead to inheritable AF (Olson et al.). Loss-of-function mutations of KCNA5 gene 
located at the N-terminus (A115V), S1 (A251T), S1-S2 linker (P307S, P310L), and C-terminus (P532L and 
R578K) have been reported in patients with idiopathic AF (Simard et al., 2005). These findings suggest that 
defective Kv1.5 channels may predispose the atria to electrical instability and arrhythmogenesis.  
B.  Signaling regulation of IKur
β-adrenergic stimulation enhances, whereas α-adrenergic stimulation inhibits IKur in human atrial myocytes 
mediated by PKA and PKC, respectively (Li et al., 1996). However, in dog atrial myocytes, both β- and 
α-adrenergic stimulation increases IKur by activating PKA and PKC (Yue et al., 1999). Whether the different 
regulation of IKur by PKC is related to the non-uniform coding (Kv1.5 and Kv3.1) (Fedida et al., 2003; Yue et 
al., 1996) remains to be studied in canine atrial myocytes. PKA activation reduces the Kvβ-induced fast 
inactivation of Kv1.5 channels by phosphorylating Kv β-subunit itself (Kwak et al., 1999). Nitric oxide 
inhibits hKv1.5 channels by a cGMP-dependent mechanism and by S-nitrosylating the channel protein 
(Nunez et al., 2006). Pyridine nucleotides modulate Kv1.5 channels by regulating the cellular redox state 
(NADPH-to-NADP+ ratio) (Tipparaju et al., 2007). Moreover, phosphatidylinositol 4,5-bisphosphate (PIP2) 
regulates the inactivation of Kv1.5 by an equilibrium binding of the N-terminus of Kvβ1.3 between 
phosphoinositides and the inner pore region of the channels (Decher et al., 2008). 
C.  Pharmacology of IKur
Human cardiac IKur and/or Kv1.5 channels are sensitive to inhibition by 4-AP (Snyders et al., 1993; Wang et 
al., 1993), but not by  tetraethylammonium (TEA) or Ba2+  (Wang et al., 1993). Low concentration of 4-AP 
(less than 50 μM) is used to separate IKur from Ito1 in human atrial myocytes (Feng et al., 1997; Li et al., 
1996).  
 The compounds capable of IKur/Kv1.5 channel block are shown in Table 1. Several antiarrhythmic drugs 
(see review, Tamargo et al., 2004), including quinidine, flecainide, and ambasilide inhibit IKur in isolated 
human atrial myocytes (Feng et al., 1997; Wang et al., 1995) and/or Kv1.5 channel expressed in mammalian 
cells (Snyders and Yeola, 1995). The L-type Ca2+ channel antagonists verapamil, diltiazem and nifedipine 
reversibly inhibits human atrial IKur (Gao et al., 2004; Gao et al., 2005). The local anesthetic drugs 
benzocaine and bupivacaine blocks Kv1.5 channels in a concentration-dependent manner (Caballero et al., 
2002). The omega-3 polyunsaturated fatty acids also inhibit human atrial IKur (Li et al., 2009) (Table 1). 
 The binding of these drugs is determined by an electrostatic component reflecting the electrical binding 
distance. The critical residues for hydrophobic binding of quinidine in hKv1.5 channels are located in the 
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putative S6 of pore-lining region and is important in determining drug affinity and specificity (Snyders and 
Yeola, 1995). Stereoselective bupivacaine block of hKv1.5 channels is determined by a polar interaction 
with T507 and two hydrophobic interactions at positions L510 and V514 (Franqueza et al., 1997). The 
binding sites for quinidine and bupivacaine in the residues of the S6 segment also determine the binding of 
neutral and acid drugs (e.g. benzocaine) (Caballero et al., 2002; Tamargo et al., 2004). Nonetheless, the 
external mouth of the channel pore formed by the P-loop and adjacent S5–S6 segments is the potential 
binding sites for some drugs (Lin et al., 2001; Tamargo et al., 2004). Long-chain polyunsaturated fatty acids 
bind to an external site to block Kv1.5 channels (Honore et al., 1994).  
  AVE0118 is one of the most studied novel atrial-selective compounds (Table 1). It blocks human atrial 
IKur and Kv1.5 channels (Gogelein et al., 2004; Wettwer et al., 2004) by binding to T479, T480, V505, I508, 
V512, and V516 within the S6 domain and pore helix region (Decher et al., 2006), and prolongs the APD in 
atrial myocytes from patients with AF (Wettwer et al., 2004). AVE0118 also inhibits hKv4.3 channels 
expressed in CHO cells and IKACh in guinea pig atrial myocytes (Gogelein et al., 2004), which may contribute 
to the atrial-selective effects on APD and ERP (effective refractory period) (Christ et al., 2008). Importantly, 
AVE0118 terminates AF in a goat model with an intravenous administration (Blaauw et al., 2004; de Haan et 
al., 2006). However, AVE0118 has a low solubility and undergoes rapid first pass hepatic metabolism with a 
short half-life in dog and pig (intravenous administration, T1/2 = 0.2–0.4 hours) (Ford and Milnes, 2008; 
Wirth et al., 2007); therefore it has not progressed into phase 3 clinical trial for anti-AF (Ford and Milnes, 
2008). AVE1231 is a chemically different compound with similar effects to those of AVE0118 (Ehrlich et al., 
2008) on IKur/Kv1.5, Ito, IKACh. It is orally effective and prolongs atrial ERP in pig and goat models with rapid 
pacing (Wirth et al., 2007). AVE1231 is undergoing phase 1 clinical trial (Ford and Milnes, 2008).   
 Diphenyl phosphine oxide (DPO) compounds selectively inhibit human atrial IKur and hKv1.5 current 
without affecting Ito1 or prolonging cardiac APD in human ventricular myocytes (Lagrutta et al., 2006).  
DPO-1 preferentially binds to the open channels of Kv1.5 with putative binding sites T480, L499, L506, 
I508, L510 and V514 (Du et al., 2010). DPO-1 significantly prolongs atrial ERP in African green monkeys 
(Regan et al., 2006) and terminates atrial arrhythmia in a canine atrial flutter model without increasing 
ventricular ERP or PR, QRS or QT interval of ECG (Stump et al., 2005).   
 ISQ-1 is an isoquinoline Kv1.5 channel blocker, prolongs atrial ERP in African green monkey and dogs, 
and terminates dog atrial flutter and/or AF (Regan et al., 2008; Regan et al., 2007). Vernakalant (RSD1235) 
blocks IKur/Kv1.5 current with a high affinity and binding to T479, T480, I502, V505, and V508 residues 
(Eldstrom et al., 2007; Fedida et al., 2005). It also inhibits the cardiac Ito1, IKACh IKr and INa at higher 
concentrations (Fedida, 2007; Fedida et al., 2005). Clinical trial has demonstrated that vernakalant converts 
AF rapidly without prolonging QT interval of ECG in patients (Fedida, 2007; Roy et al., 2004), it is under 
consideration by the FDA of USA for clinical use in treating patients with AF. 
 Acacetin is a natural flavone compound initially isolated from Chinese traditional medicine Xuelianhua 
(Saussurea tridactyla). It suppresses not only atrial IKur, but also Ito1 and IKACh. Acacetin prolongs canine 
atrial ERP without prolonging QTc interval and effectively prevents AF in a canine model after duodenal 
administration (Li et al., 2008), suggesting that acacetin may be orally effective.  
III.  The rapidly delayed rectifier K+ current IKr
Sanguinetti and Jurkiewicz demonstrate that the class III antiarrhythmic drugs notably E-4031 and sotalol 
selectively block IKr and that the drug-sensitive (IKr) and drug-resistant (IKs) components of IK differ in terms 
of voltage dependence, kinetics, rectification properties, and pharmacological sensitivity (Sanguinetti and 
Jurkiewicz, 1990). IKr and IKs play an important role in cardiac repolarization in different species including 
human (Li et al., 1996). IKr channels open rapidly upon depolarization of the action potential, but quickly 
inactivates. The channel inactivation is released following repolarization with a slow deactivation 
(Sanguinetti and Jurkiewicz, 1990). Due to this inward rectification property, IKr contributes a little during 
the plateau of cardiac action potential, and progressively increases at phase 3 repolarization of the action 
potential (Fig. 1) (Jost et al., 2005). Therefore, IKr plays a pivotal role in cardiac repolarization, especially in 
the later phases of the action potential due to its unique kinetics (Fig. 1).  
A. Molecular identification of IKr
The human ether-a-go-go–related gene (hERG or Kv11.1, or KCNH2) coding for the channels carrying the 
current resembling IKr has been identified in human heart (Sanguinetti et al., 1995), encodes the α-subunit 
underlying human cardiac IKr, and is expressed in both atria and ventricles of human heart (Gaborit et al., 
2007). Co-assembly of the regulatory β-subunit MiRP1 (minK-related peptide 1 encoded by KCNE2 gene) 
with hERG α-subunits is required to form native IKr (Gordon et al., 2008). 
 Suppression of IKr/hERG channels by medications may cause acquired long QT syndrome (LQT) 
(Farkas and Nattel, 2010; Perrin et al., 2008). Therefore, potential hERG channel blockade has been a 
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necessary screening procedure at the early stage of developing compounds (Dennis et al., 2007; Farkas and 
Nattel, 2010). Loss of function mutations of hERG and KCNE2 gene induces congenital LQT2 and LQT6, 
respectively, which are characterized in patients by prolonged QT interval of ECG, abnormal T waves and a 
risk of fatal ventricular arrhythmias named Torsades de Pointes (TdPs) (Perrin et al., 2008; Thomas et al., 
2006). However, on the other hand, gain of function mutations of hERG (McPate et al., 2009) is responsible 
for inherited short QT syndrome (SQT1), which is characterized in patients by abnormally short QT interval, 
and a high risk of atrial/ventricular fibrillation and sudden death (Brugada et al., 2004; Charpentier et al., 
2010).  
B.  Signaling regulation of IKr
Although it is generally accepted that IKr and/hERG channels are relatively insensitive to signaling 
modulation, a list of signaling molecules have been reported to regulate IKr/hERG channels, including cAMP, 
PKA, PKC, PIP2, etc. (see review, Charpentier et al., 2010). Activation of β- or α-adrenergic receptor 
suppresses hERG channels by increasing intracellular cAMP levels. PKA decreases the current amplitude, 
accelerates the deactivation and positively shifts the activation conductance via phosphorylating the hERG 
channel protein. On the other hand, intracellular cAMP may increase the current by directly binding to the 
cyclic nucleotide binding domain in C-terminus of hERG channels and negatively shifting the activation 
conductance (Thomas et al., 2006).  
PIP2 up-regulates hERG current by accelerating the activation and slowing the inactivation of the 
channels (Bian et al., 2004). The polycationic region in C-terminus of hERG channels is the potential 
electrostatic interaction sites of PIP2 (Bian et al., 2004). Stimulation of α-1A adrenoceptor decreases hERG 
current and positively shifts the activation conductance, which is related to the consumption of endogenous 
PIP2 induced by PLC (phospholipase C) activation (Bian et al., 2004). In addition, hERG channels are also 
constitutively activated by Src-family kinases and EGFR kinase via phosphorylating the tyrosine residues 
Y475 and/or Y611 (Zhang et al., 2008). Moreover, nitric oxide inhibits hERG current via an interaction with 
free radical oxygen species in a cyclic GMP-independent manner (Taglialatela et al., 1999).  
 A recent study demonstrates that chronic hypokalemia rabbits exhibit a prolonged QT interval of ECG, 
and a downregulated IKr without significantly affecting other membrane current in ventricular myocytes 
isolated from the hypokalemia rabbits. Further investigation indicates that a reduced extracellular K+ 
decreases the current amplitude, plasma membrane stability, and expression of hERG channel protein by 
accelerating internalization and degradation of hERG channels (Guo et al., 2009). This study reveals the 
potential mechanism why hypokalemia patients are susceptible to LQTs and TdPs tachyarrhythmias (Roden 
et al., 1986).  
C.  Pharmacology of IKr
IKr/hERG channels are extraordinarily sensitive to block by a large number of structurally diverse 
drugs/chemicals (Farkas and Nattel, 2010; Raschi et al., 2009). IKr/hERG blockers such as quinidine, 
d-sotalol, dofetilide, etc. have been used for many years as class III antiarrhythmic drugs, and they are 
efficacious in preventing and terminating AF and flutter, but their intrinsic arrhythmogenic activity largely 
restricts their use due to the well-known major effect of inducing LQTs and TdPs, a substrate of 
life-threatening ventricular arrhythmia.  Therefore, the class III antiarrhythmic drugs with IKr/hERG channel 
block are not an ideal medication used for treating AF.     
In addition to class III antiarrhymic drugs, many other commonly used clinical medications also block 
human IKr and hERG channels (see review, Tamargo et al., 2004), for example (Table 1), the antihistamine 
drugs terfenadine and loratadine (Crumb, 2000), the antiestrogenic drugs tamoxifen (Thomas et al., 2003) 
and clomiphene (Yuill et al., 2004), the antifugal drug ketoconazole (Takemasa et al., 2008), the 
antihypertensive drug ketanserin (Tang et al., 2008) and the antipsychotic drug ziprasidone (Su et al., 2006). 
These drugs preferentially block the open hERG channels, but also exhibit low affinity for closed and 
inactivated channels (Tristani-Firouzi and Sanguinetti, 2003). The hERG channel inhibition of the 
non-antiarrhythmic drugs is the major cause of life-threatening proarrhythmia. This has directly prompted 
the withdrawal of several clinical drugs from the market (Thomas et al., 2006). Regulatory Agencies 
therefore request that all new drug candidates be tested for this possibility. 
The binding sites of hERG channel blockers are located within the inner cavity of hERG channels. The 
individual residues that form high-affinity and lower-affinity binding sites have been identified by 
site-directed mutagenesis approaches, and the gating processes have an important influence on the 
drug-binding sites (Mitcheson, 2008). The S620 in pore helix of hERG channels is the binding site of 
dofetilide and verapamil, and an intact C-type inactivation process is also crucial for high-affinity drug 
binding (Ficker et al., 1998; Zhang et al., 1999). The binding sites of high-affinity hERG blocker MK-499 
are located on S6 transmembrane domain (G648, Y652 and F656) and pore helix (T623 and V625) of the 
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hERG channels that face the vestibule of the channels. Compounds structurally unrelated to MK-499, such 
as terfenadine and cisapride, also interact with Y652 and F656, but not with V625 (Mitcheson, J. et al., 2005). 
However, the binding site of propafenone (a lower-affinity hERG blocker) is located in the F656 residue 
alone (Witchel et al., 2004). When the drug binds within the inner cavity of the channels, they are trapped in 
the vestibule by closure of the activation gate upon repolarization. So hERG channel blockers such as the 
methanesulfonanilides MK-499 show a slow recovery from blockade (Mitcheson et al., 2005). 
In addition to the direct channel block by binding to the hERG channels, some drugs suppress IKr/hERG 
channels and induced acquired long QT syndrome in patients by interrupting the trafficking of hERG 
channels and reducing the expression of membrane hERG channel protein. The anti-protozoal drug 
pentamidine is one of examples (Kuryshev et al., 2005).   To rescue LQTs, a number of compounds have 
been developed for activating IKr/hERG channels (Table 1).   
RPR260243 is the first small molecule that activates IKr/hERG channels. It dramatically slows the 
deactivation of hERG tail current in a CHO cell line expressing hERG gene. PR260243 reverses the action 
potential-prolonging effect by dofetilide in guinea pig ventricular myocytes and reduced QT interval of ECG 
in perfused guinea pig hearts (Kang et al., 2005).   
Several potent hERG channel activators developed by Pfizer (Groton, CT) are reported with a distinct 
mechanism (Zhou et al., 2005). PD-118057 enhances hERG step and tail currents in a HEK 293 stable cell 
line in a concentration-dependent manner and is able to prevent and reverse QT prolongation and associated 
arrhythmias induced by a selective IKr blocker (i.e.dofetilide) in the arterially perfused rabbit ventricular 
wedge preparation (Zhou et al., 2005). 
NS1643 and NS3623 developed by NeuroSearch A/S (Ballerup, Denmark) increases WT hERG current 
by reducing channel inactivation, while reducing the activation in inactivation-deficient hERG mutants 
(S620T, S631A) (Hansen et al., 2006). Interestingly, mutation of the high-affinity binding site F656 for 
hERG channel blocker strengthens the agonist activity of NS1643 and NS3623, suggesting a dual mode of 
action, being both an activator and an inhibitor of hERG channels (Hansen et al., 2006). 
A-935142 is a recently developed compound by Abbott Laboratories (Abbott Park, IL) with significant 
hERG enhancement by facilitating activation, reducing inactivation, and slowing deactivation of the 
channels. It shortens cardiac APD in guinea-pig atrial myocytes and canine Purkinje fibers (Su et al., 2009).  
The putative binding sites for RPR260243 are located in S5 (L553 and F557) and an adjacent region of 
S6 (N658, V659) (Perry et al., 2007), while the binding sites of PD-118057 are located in the pore helix 
(F619) or the S6 segment (L646). Interestingly, the mutants of nearby residues in the S6 segment (C643, 
M645) enhance the drug activity of PD-118057 (Perry et al., 2009). In contrast, PD-307243, an analog of 
PD-118057, increases hERG current by remarkably slowing hERG channel deactivation and inactivation 
and holding the channels in a constitutively open state via binding to the extracellular region of the pore 
(Gordon et al., 2008). 
3-Nitro-N-(4-phenoxyphenyl) benzamide (ICA-105574) is an unique and potent hERG channel 
activator more recently developed by Icagen (Durham, NC) (Gerlach et al., 2010). It steeply increases the 
hERG current amplitudes by removing the inwardly-rectifying inactivation of the channels, negatively 
shifting the voltage-dependence of channel activation and slowing channel deactivation. It shortens cardiac 
APD in ventricular myocytes from guinea pig hearts (Gerlach et al., 2010). 
IV. The slowly delayed rectifier K+ current IKs
IKs activates slowly with almost no inactivation after activation (Charpentier et al., 2010; Sanguinetti and 
Jurkiewicz, 1990), and contributes to the phase 2 slow repolarization of cardiac action potential (Fig. 1). IKs 
has been demonstrated in cardiac tissues/myocytes from different species including human (Charpentier et 
al., 2010; Jost et al., 2005; Li et al., 1996). The physiological contribution of IKs to the human ventricular 
action potential is limited; however, during tonic sympathetic stimulation or when cardiac repolarization 
reserve is attenuated, IKs plays an important role in limiting APD prolongation due to its slow deactivation 
(Jost et al., 2005).  
 Heterogeneous expression of IKs is present in different regions of the heart. In the canine ventricle, IKs 
density is greater in epicardial and endocardial cells than in the M cells (Li et al., 2002; Liu and Antzelevitch, 
1995). The lower IKs density in M cells is considered to be related to the steeper APD-rate relations and their 
greater tendency to display longer APD and to develop EADs at slow heart rates or in response to QT 
prolonging drugs (Liu and Antzelevitch, 1995).  
A.  IKs molecular identification 
IKs channels are comprised of four pore-forming α-subunits and two accessory β-subunits, which are 
encoded by KCNQ1 (Kv7.1 or KvLQT1) and KCNE1 (minK) genes respectively (Barhanin et al., 1996; 
Sanguinetti et al., 1996). The cytoplasmic C-terminus of KCNQ1 subunit contains a tetramer assembly 
domain, in which mutations lead to tetramerization deficiency. The KCNE1 subunit dynamically engages in 
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IKs gating, and is critical for the biophysical properties of the native cardiac IKs (Charpentier et al., 2010; 
Sanguinetti et al., 1996).  
IKs density is down-regulated in failing canine (Li et al., 2002) and human (Li et al., 2004) hearts. A 
decreased IKs and KCNQ1/KCNE1 mRNA levels are found in cardiac myocytes from infarcted canine 
ventricle (Jiang et al., 2000).  Loss of function mutations in KCNQ1 gene and KCNE1 gene are associated 
with congenital LQT1 and LQT5, respectively (Charpentier et al., 2010; Splawski et al., 1997). However, 
gain of function mutations in KCNQ1 gene causes congenital SQT2 and familial AF (Charpentier et al., 
2010; Lundby et al., 2007). 
B.  Signaling regulation of IKs
It is well established that catecholamines shorten cardiac APD by enhancing IKs amplitude mediated by 
cAMP/PKA and/or PKC via β- and/or α-adrenoceptor stimulation (Sanguinetti et al., 1991; Walsh and Kass, 
1991).  Activation of PKA by cAMP or phophodiesterase inhibition increases IKs current and enhances the 
rate-dependent shortening of cardiac APD (Lo and Numann, 1998; Terrenoire et al., 2005). IKs is also 
modulated by EGFR kinase (Dong et al., 2010). In addition, IKs or KCNQ1/KCNE1 channels are regulated 
by CaMKII, nitric oxide, and PIP2, etc. Readers are recommended to refer to the recent review (Charpentier 
et al., 2010) for the detailed information of IKs regulation.   
C.  Pharmacology of IKs
Chromanols (e.g. 293B, HMR-1556) are the first group of relatively selective IKs blockers (Busch et al., 1996; 
Thomas et al., 2003) (Table 1), and show stereospecific block on IKs (Yang et al., 2000). Indapamide 
(Turgeon et al., 1994) and benzodiazepine compounds (L-735821, L-761334, etc) (Lengyel et al., 2001; 
Seebohm et al., 2003; Stump et al., 2003) also remarkably block IKs. Most of them act as open channel 
blockers. Bepridil, a Ca2+ channel blocker, inhibits recombinant cardiac IKs by binding to the closed state 
channels (Yumoto et al., 2004). The drug interaction site of IKs blockers (e.g. 293B and L-735821) is located 
in the pore loop and S6 domain of KCNQ1. T312 in the pore loop and I337, P339, P340, and A344 in the S6 
domain are the most important molecular determinants of channel block (Seebohm et al., 2003).  
Blockade of IKs usually fails to remarkably prolong cardiac APD due to the sufficient repolarization 
reserve carried by other K+ channels (Lengyel et al., 2001). However, when the repolarization reserve is 
attenuated or depleted by inherited disorders, cardiac electrical remodeling or drugs, blockade of IKs 
significantly prolongs the ventricular APD (Biliczki et al., 2002). Moreover, β-adrenergic stimulation 
increases IKs in epicardial and endocardial cells, but not in M cells. IKs is intrinsically small, and IKs block 
accentuates transmamural dispersion of repolarization (Shimizu and Antzelevitch, 1998). Similar to the IKr 
blocker, the IKs blocker is also proarrhythmic (Cheng and Incardona, 2009).  Therefore, IKs activators, like IKr 
activators, may be useful in managing the cardiac arrhythmia related to delayed repolarization. 
 The Cl- channel blockers mefenamic acid and dihydro-4,4' diisothiocyanostilbene-2,2'- disulphonic acid 
(DIDS) are the first group compounds (Table 1) that enhance the recombinant IKs by reversibly speeding up 
channel activation in a KCNE1 subunit-dependent manner (Unsold et al., 2000). Thereafter, the novel 
benzodiazepine compound R-L3 is found to enhance cardiac IKs or recombinant IKs. R-L3 stereospecifically 
activates IKs and shortens APD in guinea pig cardiac myocytes by slowing the rate of IKs deactivation and 
negatively shifting the activation conductance of IKs (Salata et al., 1998). The interaction sites of R-L3 with 
IKs channels are located in the S5 and S6 domains of KCNQ1 subunits (Seebohm et al., 2003).  
Several natural compounds are recently demonstrated to up-regulate native cardiac IKs and/or 
recombinant IKs. Tanshinone IIA is one of major active components from the Chinese traditional medicinal 
herb Danshen (Salvia miltiorrhiza ), and directly increases  recombinant IKs by accelerating the activation of 
the channels, and negatively shifting the activation conductance (Sun et al., 2008). Ephedrine, an alkaloid 
isolated from the Chinese traditional medicinal herb Mahuang (Ephedra Sinica) activates recombinant IKs, 
and negatively shifts the activation conductance. The binding sites of ephedrine on recombinant IKs are 
located in the P-loop helix F296 and Y299 of KCNQ1 (Jing et al., 2009). Ginsenoside Re, a major ingredient 
of Panax ginseng, enhances IKs via s-nitrosylating the channel protein mediated by nitric oxide in guinea-pig 
cardiomyocytes (Bai et al., 2004). Moreover, various fatty acids, including docosahexaenoic acid, lauric acid 
and oleic acid  augment IKs in a KCNE1 subunit-dependent manner (Doolan et al., 2002), and phenylboronic 
acid is also found to activate recombinant IKs (Mruk and Kobertz, 2009). 
IKs activators, like the selective IKr/hERG activators, may also offer a new approach in the treatment 
of delayed repolarization conditions in patients with acquired long QT syndrome or inherited long QT 
syndrome. The IKs activator benzodiazepine R-L3 displays a prominent antiarrhythmic propensity in 
rescuing cellular models with acquired long QT type 2 (Nissen et al., 2009).  
 
4.  Inward rectifier K+ currents 
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I.  The cardiac inward rectifier K+ current IK1
Cardiac IK1 is a strong inward rectification current, and is believed to contribute only to the phase 3 rapid 
repolarization of action potential and maintain resting membrane potential in cardiac myocytes (Anumonwo 
and Lopatin, 2010). However, our recent studies have demonstrated that two components of IK1 are activated 
during cardiac action potential, one is immediately activated by action potential depolarization, and the other 
is activated at phase 3 repolarization. The IK1 activated by depolarization with comparable time course with 
INa may also contribute to the maintenance of cardiac excitability (Fig. 1) (Li et al., 1998; Zhang et al., 2009). 
Thus, IK1 plays important roles in stabilizing the resting membrane potential, controlling cardiac APD and 
excitability (Anumonwo and Lopatin, 2010). IK1 density is higher in ventricular than in atrial myocytes, but 
there is no difference in regional cells through ventricular wall in canine and guinea pig hearts (Schram et al., 
2002), and is very low in SA and AV pacemaker cells, and therefore these cells have a more depolarized 
maximum diastolic potential (Schram et al., 2002). 
A. Molecular identification of IK1
Cardiac IK1 is encoded by Kir2.1 (KCNJ2), Kir2.3 (KCNJ4), and/or Kir2.2 (KCNJ12) (Dhamoon et al., 2004; 
Ehrlich, 2008). Heteromeric assemblies of Kir2.1, Kir2.2, and Kir2.3 subunits underlie IK1 current. The 
unique properties of individual Kir2 isoforms, as well as their region- and species-dependent expression 
patterns determine the heterogeneous profiles of IK1 in atrial and ventricular myocytes of the heart (Dhamoon 
et al., 2004).  
 Cardiac IK1 is altered under different pathophysiological conditions. IK1 is downregulated in ventricular 
myocytes from failing canine (Li et al., 2002) and human (Li et al., 2004) hearts, but no Kir2.1 mRNA 
reduction is observed (Koumi et al., 1995). In atrial myocytes from patients with chronic AF IK1 is 
up-regulated (Dobrev et al., 2002), which may be related to the selective S-nitrosylation of Kir2.1 Cys76 
residue by nitric oxide (Gomez et al., 2009). 
 Loss of function mutation of KCNJ2 causes inherited Andersen–Tawil syndrome (LQT7), which is 
characterized by periodic paralysis, specific T-U-wave patterns, and skeletal developmental abnormalities 
(Anumonwo and Lopatin, 2010; Zhang et al., 2005). On the other hand, gain of function mutation of KCNJ2 
causes inherited SQT3 and familial AF (Anumonwo and Lopatin, 2010; Priori et al., 2005; Xia et al., 2005).  
B.  Signaling regulation of IK1
It is well recognized that the conductance of IK1 is highly dependent on extracellular K+ concentration.  An 
increase in extracellular K+ concentration enhances the conductance of IK1, while the conductance disappears 
with removal of extracellular K+ (Li et al., 1998; Zhang et al., 2009). IK1 is uniquely blocked by intracellular 
polyamines (spermine, spermindine and putrescine) and Mg2+ with steep voltage dependence, which is 
believed to be the molecular mechanism of the inward rectification of IK1 (Anumonwo and Lopatin, 2010; 
Lopatin et al., 1994). However, the conclusion is made under symmetrical K+ conditions. Under 
physiological K+ conditions, an increase of intracellular Mg2+ concentration does not induce any block of IK1. 
instead of an increase in the transient outward component of IK1 (Zhang et al., 2009).  
Both α- and β-adrenergic stimulation suppress IK1 in a PKA and/or PKC-dependent way (Karle et al., 
2002; Koumi et al., 1995). PIP2 activates IK1 via direct electrostatic interaction between the positively 
charged residues in the cytoplasmic region of the channels and the negative phosphate head group of PIP2 
(Xie et al., 2008). PIP2 is also an important co-factor of other regulators that modulate IK1 channels (Xie et 
al., 2007). Kir2 channels are down-regulated by membrane cholesterol level (Levitan, 2009). The 
extracellular H+ regulates IK1 in species/tissue-dependent manner, possibly reflecting channel subunit 
composition (Anumonwo and Lopatin, 2010). Tyrosine kinase activation reduces the membrane density of 
Kir2.1 channels via promoting channel endocytosis (Tong et al., 2001). 
 In addition, Kir2.1 channels are post-transcriptionally suppressed by miRNA-1 in ischemia/reperfusion 
myocardium (Yang et al., 2007). The great reduction of miRNA-1 levels may also contribute to the 
up-regulation of Kir2.1 subunits and the increased IK1 in patients with AF (Girmatsion et al., 2009). 
C.  Pharmacology of IK1
Ba2+ is a well-known IK1 blocker with an IC50 of 20 μM (Wible et al., 1995) (Table 1). Some antiarrhythmic 
drugs, such as amiodarone and azimilide, show an inhibitory effect on IK1 (see review, Tamargo et al., 2004).  
Blockade of IK1 may cause cardiac diastolic (i.e. resting membrane potential) depolarization, an 
proarrhythmic effect that offsets the membrane potential more close to the threshold potential of Na+ 
channels therefore reduces cardiac excitability. IK1 block also slows conduction velocity due to a 
voltage-dependent inactivation of Na+ channels, and prolongs the QT interval (Kleber, 1994). Therefore the 
drug that specifically blocks IK1 may not be realistic for antiarrhthima. The compound RP58866 is initially 
designed to specifically block IK1, and is effective in treating ventricular arrhythmias induced by 
ischemia/reperfusion in rat, rabbit, and primate (Rees and Curtis, 1993). Later studies demonstrate that 
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RP58866 is a non-selective K+ channel blocker. In addition to inhibition of IK1, RP58866 also suppresses Ito1, 
IKr, IKs, and IKACh (Brandts et al., 2000; Yang et al., 1999).  
II. The acetylcholine-activated K+ current IKACh
Cardiac IKACh is one of G protein-coupled inwardly-rectifying K+ channels. It is predominantly present in 
sinus node, atrial myocardium, and atrioventricular node, but largely sparse in ventricles of the heart 
(Dobrzynski et al., 2001; Gaborit et al., 2007; Schram et al., 2002). Activation of IKACh by parasympathetic 
signals such as acetylcholine through M2 muscarinic receptors causes an inward rectifier K+ current which 
hyperpolarizes the membrane potential, shortens cardiac APD, slows the spontaneous firing rate of 
pacemaker cells in sinus and atrial-ventricular nodes, and delays the atrioventricular conduction (Ehrlich, 
2008; Tamargo et al., 2004). The heterogeneity of IKACh expression within and between the left and right 
atria correlates with potentially proarrhythmic ability of vagal nerve stimulation (Arora et al., 2007). In 
addition, IKACh plays an important role in the generation of AF (Atienza et al., 2006).  
A.  Molecular identification of IKACh
IKACh channel in the heart is a heterotetramer constituted by two Kir3.1 (KCNJ3/GIRK1) and two Kir3.4 
(KCNJ5/GIRK4) subunits (Anumonwo and Lopatin, 2010; Corey et al., 1998). 
 IKACh is remodeled in heart disorders (Borlak and Thum, 2003; Brundel et al., 2001).  IKACh current is 
transcriptionally down-regulated in chronic AF, but an agonist-independent (i.e., active in the absence of 
agonist) constitutively active form of IKACh contributes to human chronic AF (Dobrev et al., 2005; Voigt et 
al., 2007). Loss of function mutation of Kir3.4 gene is detected in, but not associated with clear atrial 
disorders (Calloe et al., 2007). 
B.  Signaling regulation of IKACh
In addition to the acetylcholine-muscarinic receptor-G protein pathway, cardiac IKACh may be activated by 
other G-protein coupled receptors including A1-adenosine, α-adrenergic, etc. Adenosine activates rat atrial 
IKACh (Bosche et al., 2003).  Activation of α1-adrenoceptor reduces IKACh current in atrial myocytes 
(Anumonwo and Lopatin, 2010). In canine atrial cardiomyocytes, β1-adrenergic stimulation enhances 
IKACh current via cAMP-induced activation of PKA whereas α1A-adrenergic stimulation suppresses 
IKACh current via PLC-mediated activation of PKC (Yeh et al., 2007). PIP2 up-regulates IKACh in diverse 
manners: direct interaction with the channels or with Gβ/γ subunits, and via the downstream PKC action 
(Keselman et al., 2007). Recombinant Kir3.1/Kir3.4 channels are regulated by PKA phosphorylation. Three 
phosphorylation sites (Ser385, ser401 and thr407) located within the C-terminus of Kir3.1 are responsible 
for PKA phosphorylation and the regulation of IKACh channels (Mullner et al., 2009). Gβ/γ also affects the 
trafficking of IKACh channels by forming Gβ/γ-Kir3.1/Kir3.4 complexes during channel biosynthesis and 
trafficking (Robitaille et al., 2009). 
C.  Pharmacology of IKACh
The atrial-specific localization and the functionally upregulation (increased constitutive activity) of IKACh 
during AF make it possible a promising antiarrhythmic target devoid of ventricular side effects (Ehrlich, 
2008; Kozlowski et al., 2009). Much effort is made to develop selective IKACh blockers (Dobrev and Nattel, 
2010) (Table 1). 
 Tertiapin, a 21-residue peptide toxin from honey bee venom, and its derivative tertiapin-Q directly block 
IKACh with nanomolar affinity by binding to the external end of the ion conduction pore (Jin and Lu, 1998). 
Tertiapin blocks IKACh current in a receptor- and voltage-independent manner without affecting other cardiac 
ionic currents (Drici et al., 2000). It has been demonstrated that tertiapin terminates AF without affecting 
ventricular repolarization in canine AF model (Hashimoto et al., 2006). 
 The benzopyran compound NIP-151 significantly inhibits IKACh, and effectively terminates AF in canine 
model with an atrial-specific ERP-prolonging profile and lower risk of proarrhythmia compared with IKr 
blockers (Hashimoto et al., 2008). AVE0118, in addition to inhibiting Ito1 and IKur, blocks IKACh channels, 
and demonstrates atrial-specific antiarrhythmic effects in animal models (Blaauw et al., 2004; Gogelein et al., 
2004). AVE1231, which has improved pharmacokinetic properties compared to AVE0118, shows similar 
effects on IKACh current (Wirth et al., 2007). The natural flavone accacetin also inhibits IKACh along with IKur 
and Ito1 and prevents AF in a canine model (Li et al., 2008) (Table 1).     
 In addition, the benzothiazepine compound JTV-519 (K201) inhibits IKACh and suppresses experimental 
AF in isolated guinea pig hearts (Nakaya et al., 2000). SD-3212 (levo-semotiadil fumarate), a novel 
benzothiazine Ca2+ channel antagonist, also inhibits IKACh channels by depressing the function of the channel 
itself and/or associated GTP-binding proteins (Hara and Nakaya, 1995) and shows anti-atrial arrhythmic 
effect (Fujiki et al., 1997). 
 Moreover, classical antiarrhythmic agents with a broad channel blockade profile, such as amiodarone 
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and the structurally related derivatives, dronedarone (SR33589) and KB130015, also block cardiac IKACh 
with high potency by either disrupting G-protein-mediated activation or directly inhibiting interaction with 
the channel protein (Guillemare et al., 2000; Mubagwa et al., 2003). Blockade of IKACh by flaceinide 
contributes at least in part to the anti-AF effect in humans.   
III.  Cardiac ATP-sensitive K+ current, IKATP
Cardiac IKATP is carried by ATP sensitive K+ channels. KATP channels are closed at physiological 
intracellular ATP concentrations, and activated by a decrease in ratio of intracellular ATP/ADP (Noma, 
1983). KATP channels act as a unique metabolic sensor or a coupling between the cell metabolic status and 
the cellular membrane potential. IKATP plays a pivotal role in maintaining cardiac homeostasis under stress, 
such as myocardial ischemia/reperfusion and hypoxia, and mediate the ischemia-induced 
electrophysiological changes and cardioprotective effect of preconditioning (Zingman et al., 2007). 
Activation of IKATP shortens cardiac APD by accelerating the phase 3 repolarization, reduces Ca2+ influx 
thereby preventing cardiac Ca2+ overload, preserves ATP levels (energy-sparing effects) and increases cell 
survival during myocardial ischemia (Tamargo et al., 2004; Tsuboi et al., 2004). On the other hand, 
activation of IKATP may also be ‘cardiotoxic’ by inducing re-entrant ventricular arrhythmias (Tamargo et al., 
2004; Zunkler, 2006). 
A.  Molecular identification of IKATP
KATP channels are composed of Kir 6.x-type subunits and sulfonylurea receptor (SUR) subunits (Fig. 2), 
along with additional components (Stephan et al., 2006). They are further identified by their location within 
the cell as being either sarcolemmal (sarcKATP) or  mitochondrial (mitoKATP) (Foster et al., 2008; O'Rourke, 
2004). Cardiac sarcKATP channels are a hetero-octameric complex composed of four inwardly-rectifying 
Kir6.2 channel pore subunits (encoded by KCNJ11), which confer inhibition by ATP, and four modulatory 
sulfonylurea receptor SUR2A (encoded by ABCC9) subunits (Billman, 2008; Tamargo et al., 2004). 
However, the subunit of mitoIKATP remains to be determined conclusively (Foster et al., 2008; O'Rourke, 
2004). A recent study demonstrated that the SUR2-IES is the β-subunit of mitoKATP channels (Ye et al., 
2009).  The SUR2A subunit (Fig. 2) has three hydrophobic transmembrane domains (TMD0, TMD1 and 
TMD2) that likely include five, six and six transmembrane segments respectively, with two hydrophilic 
nucleotide binding folds (NBF1 and NBF2) following TMD1 and TMD2 (Conti et al., 2001). SUR2A 
contains ATPase activity harbored within NBF2 and, to a lesser degree, NBF1. NBD1/NBD2 assembly 
provides a molecular substrate that determines the optimal catalytic activity in SUR2A (Park et al., 2008).  
 Defective mutations and polymorphisms in Kir6.2 are associated with increased risk of many kinds of 
metabolic disorders (Reyes et al., 2009). Disruption of sarcIKATP activity impairs cardiac adaptation to stress 
such as systolic overload (Reyes et al., 2009). Kir6.2−/− mice present with an aberrant regulation of 
cardiomyocyte membrane excitability and Ca2+ handling, and are susceptible to ventricular arrhythmias and 
sudden death following sympathetic stimulation (Zingman et al., 2002). 
B.  Signaling regulation of IKATP
In addition to regulation by the intracellular ATP and ADP (Noma, 1983), IKATP is regulated by PKC, PTK, 
PIP2, nitric oxide, and many other signaling molecules.  PKC activates cardiac IKATP channels at near 
physiological levels of ATP and induces ischemic preconditioning (Light et al., 1996). Isoform-dependent 
activation of PKC contributes to the persistent opening of IKATP channels during reoxygenation and 
reperfusion (Ito et al., 2001). Mitochondrial connexin 43 (Cx43) is recently found to regulate mitoKATP and 
protects cardiac cells from death. Genetic Cx43 deficiency, pharmacological Cx43 inhibition by 
carbenoxolone or by mimetic peptide substantially reduces diazoxide-mediated stimulation of mitoKATP 
channels. Suppression of mitochondrial Cx43 inhibits mitoKATP channel activation by PKC (Rottlaender et 
al., 2010). A recent review (Akrouh et al., 2009) is recommended for the detailed information of KATP 
channel regulation.  
C.  Pharmacology of IKATP
In addition to inhibition by intracellular ATP (Noma, 1983), KATP channels can be blocked by antidiabetic 
drugs including the sulfonylureas, e.g. glibenclamide, glicazide, glipizide, glimepiride, tolbutamide and the 
glinides such as repaglinide, nateglinide, mitiglinide as well as some anti-arrhythmic drugs (e.g. flecainide) 
(Tamargo et al., 2004). Sulfonylurea drugs bind directly to the SUR region in the loop between TM15 and 
TM16 in TMD2 and S1237. These drugs have been widely used to regulate KATP channel activity (Conti et 
al., 2001) 
Because KATP channels in pancreatic β-cells and smooth muscle regulate insulin secretion and vascular 
tone (Seino and Miki, 2003), IKATP blockers may therefore induce hypoglycemia and coronary 
vasoconstriction; however, cardioselective KATP channel blockers may be beneficial for treating cardiac 
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disorders. The cardioselective KATP channel blocker HMR 1098 (clamikalant) (Liu et al., 2001) reduces the 
cardiac APD shortening induced by hypoxia and prevents ventricular fibrillation induced by coronary artery 
occlusion in post-infarcted conscious dogs at doses that have no effect on insulin release, blood pressure or 
coronary blood flow (Grover and Garlid, 2000). Thus, specific cardiac IKATP channel blockers may represent 
a new therapeutic approach to treat ischemia-induced ventricular arrhythmias with little or no side effects 
(Billman, 2008).  
The KATP channel activators, e.g. pinacidil, cromakalim, rimakalim and nicorandil, are found to open 
KATP channels by binding to two distinct regions of TMD2, the intracellular loop joining TM13 and TM14 
and between TM15 and TM16 (residues K1249 and T1253) (Moreau et al., 2000).  These compounds have 
ischemia preconditioning effect and are cardioprotective in experimental myocardial ischemia/reperfusion 
models and in patients with acute myocardial infarction (Grover and Garlid, 2000). However, they also 
activate vascular KATP channels (Kir6.1/SUR2B) and induce hypotension which limits their use in the 
treatment of myocardial ischemia.   
It is believed that sarcKATP channels are responsible for ischemia preconditioning (Grover and Garlid, 
2000). Indeed the mitoKATP channel activator diazoxide mimics the ischemic preconditioning, and the effect 
is countered by the selective mitoKATP blocker 5-hydroxydecanoate (5-HD). The selective mitoKATP 
opener BMS-191095 exerts cardioprotective effects without shortening APD or inducing hypotension effect 
(Grover et al., 2001). Therefore, cardioselective and/or mitoKATP channel blockers and activators (Table 1) 
would be beneficial in protection of cardiac ischemia/reperfusion.   
5.  Cardiac two pore K+ current K2P 
The two pore domain K+ (K2P) channels have been discovered for more than a decade, and they support 
background K+ currents and maintain membrane potential in many cell types (see reviews, Gurney and 
Manoury, 2009; Judge and Smith, 2009). The distinct K2P channels including four subfamilies of TASK, 
TWIK, TREK and THIK. K2P channels comprise of four transmembrane domains and two pore-forming P 
loops arranged in tandem (Fig. 2) (Gurney and Manoury, 2009).  K2P channels are sensitive to membrane 
stretch, pH variation, phospholipids, fatty acids, volatile anaesthetics and G-protein coupled receptors 
(Bayliss and Barrett, 2008); however, they are insensitive to conventional K+ channel blockers such as 4-AP, 
TEA, Ba2+, Cs+ and glibenclamide (Gurney and Manoury, 2009; Tamargo et al., 2004).  
In the heart, the resting membrane potential and cell excitability is predominantly contributed by IK1.  
Although the mRNAs of several K2P channels (e.g. TREK-1 and TASK-1) are detected, the proposed 
contribution of these channels to cardiac background currents and cellular physiology are still unclear. No 
functional current has been recorded in human cardiomyocytes (Gurney and Manoury, 2009). However, 
because K2P channels are sensitive to cellular or extracellular signals (pH level, membrane stretch, etc), so 
they likely act as cellular sensor and transducers (O'Connell et al., 2002). Effort should be made in the future 
to find out pharmacological tools that select for these channels in order to further understand the 
physiological importance and whether these channels regulate cardiac functions (Gurney and Manoury, 2009; 
O'Connell et al., 2002; Tamargo et al., 2004). 
6.  Conclusion 
The electrical properties of atria and ventricles of human heart are different in the distinct roles of 
cardiac physiology. Studies on cellular electrophysiology and ion channels have greatly improved our 
understanding of atrial and ventricular arrhythmias at cellular and molecular levels, including atrial 
fibrillation and life threatening ventricular arrhythmias. Cardiac K+ channels have been recognized as 
potential therapeutic targets. The understanding of the ion channel distribution in the atria and ventricles 
and the pathophysiological alteration in different ion channels induced by genetics, diseases and/or 
medications has provided a basis for rational design of safer and more effective K+ channel blockers 
and/or activators to prevent/treat atrial fibrillation and/or ventricular arrhythmias.  
 The improved understanding of molecular basis for cardiac IKr and IKs makes it possible for the 
pharmaceuticals to develop selective IKr/hERG channel activators (e.g. PR260243, PD-118057, etc.) 
and/or IKs activators (e.g. RL-3, tanshinone, etc), which may offer a new approach in the treatment of 
delayed repolarization conditions in patients with acquired long QT syndrome or inherited long QT 
syndrome, congestive heart failure, and diabetes.  In  the last decade, effort has been made to develop new 
anti-arrhythmic agents with safer and more effective than those presently used, especially ‘atrial-selective 
drugs’ that target cardiac ion channel(s) that are exclusively or predominantly expressed in the atria to avoid 
the proarrhythmic effect of class III antiarrhthmic drugs. IKur is a major repolarizing current in human atria, 
but not in the ventricles, so that blocking of IKur is thought to be a promising target for atrial-specific therapy 
of AF. IKACh channels are predominantly present in atria, but largely sparse in ventricles of the heart. 
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Compounds that selectively inhibit IKur (e.g. DPO-1, ISQ-1, etc.) or IKACh (e.g. tertiapin, tertiapin-Q, etc.) 
or both I  and I  (e.g. AVE0118, Kur KACh AVE1231, acacetin, etc.) have been demonstrated to terminate or 
prevent experimental AF. Therefore, these compounds are thought to be a promising target for 
atrial-specific therapy of AF.  Because I  channels are more significant for atrial repolarization than 
that in ventricles, the compounds with I  block (e.g. vernakalant, AVE0118, acacetin, etc.) would be a 
plus for anti-AF. 
to1
to1
These atrial-selective compounds should be further studied to demonstrate whether 
they are the desired drugs that are not only effective in clinically relevant AF animal models, but also 
satisfied  in oral bioavailability and safe in animals following repeat dosing; and, crucially, clinical 
efficacy and safety. The studies on cardiac selective KATP channel inhibitor (e.g. clamikalant) or 
mitoKATP activators (e.g. atpenin A5, P1705) (Table 1) are being progressed for the protection of cardiac 
ischemia/reperfusion. The remained question is whether IK1 is a target for developing specific activators 
to treat certain type of arrhythmias related to delayed reploarization.   
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Drug Ito1/Kv4.3 IKur/Kv1.5 IKr/hERG IKs IKACh IKATP IK1 Species References 
Blocker          
Acacetin 9.3 μM 3.2 μM   4 μM   Human/GP  atrial myocytes (Li et al., 2008) 
Adenosine       20.7 μM Rat/GP cardiac myocytes (Wang et al., 2006) 
AMP579        4.1 μM Rat/GP atrial myocytes (Wang et al., 2006) 
AVE0118 3.4 μM 6.2 μM 10 μM     CHO (Gogelein et al., 2004) 
AVE1231 5.9 μM 3.6 μM   8.4 μM   Pig atrial myocytes/CHO (Wirth et al., 2007) 
BaCl2       19.6 μM hIRK/Oocytes (Wible et al., 1995) 
Cinnamyl-3,4-dihydroxy-alp
ha-cyanocinnamate  5.7 μM      CHO (Gong et al., 2008) 
Citalopram  2.8 μM      CHO (Lee et al., 2010) 
Clomiphene   180 nM     HEK293 cells (Yuill et al., 2004) 
Clotrimazole 29.5 μM 7.6 μM 3.6 μM 15.1 μM    Human atrial myocytes/HEK293 (Tian et al., 2006) 
Diltiazen 29.2 μM 11.2 μM      Human atrial myocytes (Gao et al., 2005) 
DPO-1  20 nM      Human atrial myocytes/CHO (Lagrutta et al., 2006) 
Docosahexaenoic acid 4.1 μM 4.3 μM      Human atrial myocytes (Li et al., 2009) 
Eicosapentaenoic acid 6.2 μM 17.5 μM      Human atrial myocytes (Li et al., 2009) 
JTV-519(K201)     <2.4 μM   GP atrial myocytes (Nakaya et al., 2000) 
KB130015     0.6 μM   GP atrial myocytes (Brandts et al., 2004) 
Ketanserin   110 nM     HEK293 (Tang et al., 2008) 
Ketoconazole   1.9 μM     HEK293 (Takemasa et al., 2008) 
Table 1. Pharmacological blockers and activators of cardiac potassium channels 
Drug Ito1/Kv4.3 IKur/Kv1.5 IKr/hERG IKs IKACh IKATP IK1 Species References 
LY294002  7.9 μM      CHO cells (Wu et al., 2009) 
Nifendipine 26.8 μM 8.2 μM      Human atrial myocytes (Gao et al., 2005) 
NIP-151     1.6 nM   HEK293 cells (Hashimoto et al., 2008) 
Nordihydroguaiaretic acid  16.4 μM      CHO cells (Gong et al., 2008) 
Quinidine   0.6 μM     CHO cells (McPate et al., 2006) 
Raloxifene 0.9 μM 0.7 μM      Human atrial myocytes (Liu et al., 2007) 
S0100176  0.7 μM      Oocytes (Decher et al., 2004) 
SD-3212     <0.4 μM   GP atrial myovytes (Hara and Nakaya, 1995) 
Activator          
A-312110      4.3 nM  GP cells (Davis-Taber et al., 2003) 
A-935142   60 μM     HEK293 cells (Su et al., 2009) 
Adenosine 2.3 μM       Rat cardiac myocytes (Wang et al., 2006) 
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Table 1 (continued) 
Spironolactone 
Canrenoic acid 
27%/1 μM 
27%/1 nM 
23%/1 μM 
19%/1 nM 
 
104 nM 
38%/1 μM
223 nM    CHO/Ltk−
(Gomez 2005 
Caballero, 2003) 
Tertiapin/Tertiapin Q     10 nM   Oocytes (Jin and Lu, 1998) 
U50488H 12.4 μM 3.3 μM      Human atrial myocytes (Xiao et al., 2003) 
U73122/U73343     0.5 μM   HEK293 cells (Klose et al., 2008) 
Verapamil  3.2 μM      Human atrial myocytes (Gao et al., 2004) 
Vernakalant 30 μM 13 μM 21 μM     HEK293 cells (Fedida et al., 2005) 
Verrucotoxin      16 μg/ml  GP atrial myocytes (Wang et al., 2007) 
Ziprasidone   120 nM     HEK293 cells (Su et al., 2006) 
 
 
Table 1 (continued) 
Drug Ito1/Kv4.3 IKur/Kv1.5 IKr/hERG IKs IKACh IKATP IK1 Species/cell type References 
AMP579  8.3 μM       Rat cardiac myocytes (Wang et al., 2006) 
BMS-191095      83 nM  Reconstituted sarcIKATP (Grover et al., 2001) 
Atpenin A5      1 nM  Rat mitoIKATP (Wojtovich and Brookes, 2009) 
Ephedrine    50 nM    HEK293 cells (Jing et al., 2009) 
Ginsenoside Re    3 μM    GP ventricular myocytes (Bai et al., 2004) 
ICA-105574   0.5 μM     HEK293 cells (Gerlach et al., 2010) 
KB130015   12.2 μM     HEK293 cells (Gessner et al., 2010) 
NS1643   10.5 μM     HEK293 cells (Hansen et al., 2006) 
NS3623   79.4 μM     Oocytes (Hansen et al., 2006) 
P1705      68 nM  Rabbit mitoIKATP (Oldenburg et al., 2003) 
PD-118057   3 μM     HEK293 cells (Zhou et al., 2005) 
PD-307243   <1 μM     CHO cells (Gordon et al., 2008) 
Phenylboronic acid    1.6 mM    Oocytes (Mruk and Kobertz, 2009) 
Resveratrol    10 μM    GP ventricular myocytes (Zhang, Y. et al., 2006) 
R-L3    < 1 μM    GP ventricular myocytes/Oocytes (Salata et al., 1998) 
RPR260243   <3 μM     HEK293 cells (Kang et al., 2005) 
Tanshinone IIA    64.5 μM    HEK293 cells (Sun et al., 2008) 
TEA     2.5 mM   GP atrial myocytes (Wang and Armstrong, 2000) 
Data are expressed as IC50 (for blockers) or EC50 (for activators) values (concentrations producing 50% inhibition or enhancement of the current or half-maximal effects), 
and some values are estimated according to the reference, which are mainly from the reports after 2003. Please refer to the review (Tamargo et al., 2004) for the information 
before 2003.  GP, guinea pig; CHO, Chinese hamster ovary. 
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Figure 1. Ionic current contribution to human atrial and ventricular action potentials.  The graph 
schematically shows that the major ionic currents contribute to the action potential waveforms at 
different phases. The action potentials are recorded from a human atrial myocyte and ventricular 
myocyte. The depolarizing inward (downward) currents and repolarizing outward (upward) currents 
represent the potential contribution to the action potentials.  
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Figure 2.  Schematic topology of the potassium channels subunits. A.  6-TM subunits, the Kv channels 
are composed of four subunits each containing six-transmembrane segments (S1-S6) and one conducting 
pore (P) domain between S5 and S6 with a positively charged voltage sensor S4. The auxiliary β-subunit 
may be cytoplasmic protein (Kvβ,for IKur and Ito1) or single transmembrane protein (KCNE1, for IKr and IKs). 
The inset shows the general assembly of K+ channels. The channel tetramer may be homogenous (with four 
identical α-subunits) or heterogenous (with four different α-subunits). B. 2-TM subunits, the α-subunits of 
the inward rectifier K+ channels (Kir2.x, Kir 3.x, and Kir6.x) contain four subunits each containing two 
transmembrane segments (M1 and M2) with one pore.  Cardiac IKATP channels are composed of four 
α-subunits (Kir6.2), and four β-subunits sulfonylurea receptor (SUR2A) containing three transmembrane 
domains (TMD0-TMD2). C, 4-TM subunits. K2P channels have four–transmembrane segments (M1-M4) 
with two pores.  
 
 
